Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017;4(2):109-115.
doi: 10.14283/jpad.2017.12. Epub 2017 Apr 25.

Defining Disease Modifying Therapy for Alzheimer's Disease

J Cummings  1 , N Fox  2
Affiliations

Defining Disease Modifying Therapy for Alzheimer's Disease

J Cummings et al. J Prev Alzheimers Dis. 2017.

Abstract

Background: Disease-modifying therapies (DMTs) are urgently needed to treat the growing number of individuals with Alzheimer's disease (AD) or at immanent risk for AD. A definition of DMT is required to facilitate the process of DMT drug development.

Process: This is a review of the state of the science with regard to definition and development of DMTs.

Results: A DMT is as an intervention that produces an enduring change in the clinical progression of AD by interfering in the underlying pathophysiological mechanisms of the disease process that lead to cell death. Demonstration of DMT efficacy is garnered through clinical trial designs and biomarkers. Evidence of disease modification in the drug development process is based on trial designs such as staggered start and delayed withdrawal showing an enduring effect on disease course or on combined clinical outcomes and correlated biomarker evidence of an effect on the underlying pathophysiological processes of the disease. Analytic approaches such as showing change in slope of cognitive decline, increasing drug-placebo difference over time, and delay of disease milestones are not conclusive by themselves but support the presence of a disease modifying effect. Neuroprotection is a related concept whose demonstration depends on substantiating disease modification. No single type of evidence in itself is sufficient to prove disease modification - consistency, robustness, and variety of sources of data will all contribute to convincing stakeholders that an agent is a DMT.

Conclusion: DMT is defined by its enduring effect on processes leading to cell death. A variety of types of data can be used to support the hypothesis that disease modification has occurred.

Keywords: Alzheimer’s disease; amyloid; biomarker; disease modifying therapy; staggered start.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Stages of Alzheimer’s disease applicable to development of disease modifying therapies
Figure 2
Figure 2
Analytic observations consistent with disease modification
See this image and copyright information in PMC

References

    1. Sosa-Ortiz AL, Acosta-Castillo I, Prince MJ. Epidemiology of dementias and Alzheimer’s disease. Arch Med Res. 2012;43:600–608. - PubMed
    1. Pietrzak RH, Lim YY, Ames D, et al. Trajectories of memory decline in preclinical Alzheimer’s disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of ageing. Neurobiol Aging. 2015;36:1231–1238. - PubMed
    1. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012;367:795–804. - PMC - PubMed
    1. U.S. Food and Drug Administration. Guidance for Industry Alzheimer’s Disease: Developing drugs for the treatment of early stage disease. Washington, D.C.: 2013. [updated 2/2013]. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformati....
    1. European Medicine Agency; Committee For Medicinal Products For Human Use. Draft guideline on the clinical investigation of medicines for the treatment of Alzheimer’s disease and other dementias. 2016 EMA/CHMP/539931/2014.

LinkOut - more resources